News
Published Data as of
Novo Nordisk reported on November 24, 2025 that oral semaglutide showed no slowing of Alzheimer's progression compared with placebo in two large trials.1 The evoke and evoke+ trials enrolled some 3800 people with early Alzheimer's and followed them for 2 years.1 PepBank holds 934 publications with findings in people for semaglutide, as of November 15, 2026.2 The FDA approved Rybelsus in 2019 for glycemic control in adults with type 2 diabetes.3
Novo Nordisk reported that two large randomized, placebo-controlled trials of oral semaglutide in people with Alzheimer's showed no slowing of disease progression compared with placebo.1 The trials, called evoke and evoke+, enrolled some 3800 people in the early stages of Alzheimer's and followed them for 2 years.1 Science reported the result and named Novo Nordisk, the Danish drugmaker, as the sponsor of the trials.1
Semaglutide is one of the peptides in PepBank, with 966 studies that gave it as of November 15, 2026.2 The semaglutide studies hold 4624 results in PepBank's records.2
By evidence class, PepBank holds 934 publications with findings in people and 20 with findings in animals.2 PepBank also lists 663 registered trials that test semaglutide.2
| Evidence class | Publications | Findings |
|---|---|---|
| In people | 934 publications with findings in people | 4515 findings in people2 |
| In animals | 20 publications with findings in animals | 59 findings in animals2 |
| In cells or tissue | 3 publications with findings in cells or tissue | 8 laboratory findings in cells or tissue2 |
| Predicted by a computer model | 13 publications with findings predicted by a computer model | 42 findings predicted by a computer model2 |
The FDA approved Rybelsus in 2019 for glycemic control in adults with type 2 diabetes, with diet and exercise.3 The FDA indication for Rybelsus also includes reducing the risk of major adverse cardiovascular events in high-risk adults with type 2 diabetes.3 The EMA approved Rybelsus in 2020 for adults with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise.4
One trial in people enrolled adults with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or both. In that trial, oral semaglutide lowered major cardiovascular events versus placebo (hazard ratio 0.86).5 A trial analysis in adults with type 2 diabetes and ASCVD, CKD, or both examined body weight. In these people, oral semaglutide reduced body weight versus placebo by an estimated 3.26 percentage points at week 156.6
PepBank's regulatory record lists Rybelsus as a semaglutide product approved in the US and EU, with the year 2019.7 The FDA approved Rybelsus in 2019, and the EMA approved Rybelsus in 2020, both for adults with type 2 diabetes.3,4 Science reported that the Alzheimer's trials tested a pill form of semaglutide.1
The evoke and evoke+ trials enrolled some 3800 people in the early stages of Alzheimer's. The trials followed them for 2 years.1 Science described them as the largest, longest GLP-1 trials ever conducted in a neurodegenerative disease.1 Novo Nordisk, the Danish drugmaker, sponsored the trials.1
Novo Nordisk canceled the planned 1-year extension of the evoke trials.1 The company decided this after it saw no effect from semaglutide on the Clinical Dementia Rating-Sum of Boxes (CDR-SB). That scale is a widely used measure of cognition and function in Alzheimer's trials.1
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated